Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Prevalence of Subclinical Atherosclerosis and Its Associated Factors in Hyperlipidemic Korean Adults With Diabetes (ALTO)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01264263
First received: December 17, 2010
Last updated: March 12, 2012
Last verified: March 2012

December 17, 2010
March 12, 2012
January 2011
April 2011   (final data collection date for primary outcome measure)
  • Measurement of intima media thickness, visit 1 [ Time Frame: Visit 1 ] [ Designated as safety issue: No ]
  • Measurement of intima media thickness, visit 2 [ Time Frame: Visit 2 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01264263 on ClinicalTrials.gov Archive Site
  • hs-C-Reactive Protein, visit 1 [ Time Frame: Visit 1 ] [ Designated as safety issue: No ]
  • hs-C-Reactive Protein, visit 2 [ Time Frame: Visit 2 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Prevalence of Subclinical Atherosclerosis and Its Associated Factors in Hyperlipidemic Korean Adults With Diabetes
Prevalence of Subclinical Atherosclerosis and Its Associated Factors in Hyperlipidemic Korean Adults With Diabetes

This study is to investigate correlation between Carotid Intima Media Thickness (cIMT) and several factors such as; hs C-reactive protein (CRP), HbA1c, lipid profile in Korean diabetic patients with atherosclerosis. Total 360 patients will be enrolled through 6 sites.

MC MD

Observational
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples Without DNA
Description:

Whole blood and serum, urine

Probability Sample

360 patients who has diabetic mellitus with dyslipidemia

  • Diabetes Mellitus
  • Dyslipidemia
Not Provided
1
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
181
April 2011
April 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • patients with Diabetic Mellitus
  • patients with dyslipidemia

Exclusion Criteria:

  • patients who have established cardiovascular disease
  • patient using NSAID
Both
20 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT01264263
NIS-CKR-DUM-2010/1
No
AstraZeneca
AstraZeneca
Not Provided
Study Chair: Dongsun Kim Hanyang University
Principal Investigator: Eunkyung Hong Kangnam Sacred Heart Hospital
Principal Investigator: Hyunsang Kwon Yeoido Saint Mary's Hospital
Principal Investigator: Dongjoon Kim Ilsan-Paik Hospital
Principal Investigator: Sungjin Lee Hallym University Hospital
Principal Investigator: Singon Kim Korea University Anam Hospital
AstraZeneca
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP